Closely-held Vasomune Therapeutics found the right partner last month in AnGes (TYO:4563) to co-develop its Vasculotide drug candidate for the treatment of diseases associated with blood vessel leakage and pulmonary inflammation, with a lead program in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).
Read MoreEvoke Pharma’s (NASDAQ:EVOK) discovery that its metoclopramide nasal spray, known as Gimoti, to treat symptoms of gastroparesis, a delayed emptying of stomach contents, reduced symptoms in women, but not in men, and that metoclopramide has significantly different exposure in men, compared with women, led the company to file a female-only NDA with the FDA in June.
Read MoreA new drug discovery paradigm, PLEOTHERAPY, developed by Pharnext SA (FR0011191287-ALPHA) is based on big genomic data, artificial intelligence, and rigorous experimental analysis that involves innovative combinations of repositioned drugs, called PLEODRUGs, to treat orphan and common neurodegenerative diseases with high unmet medical needs.
Read MoreExicure (OTCQB:XCUR) expects to report data around the end of the third quarter of 2018 from two Phase 1 clinical trials, one in mild-to-moderate psoriasis and one in healthy volunteers with its lead spherical nucleic acid (SNA) drug candidates.
Read MoreClosely-held Perimeter’s next-generation wide-field optical coherence tomography (OCT) technology for tumor tissue specimens has imaging resolution 10 times higher than ultrasound and 100 times higher than MRI.
Read MoreASLAN Pharmaceuticals (NASDAQ:ASLN; TPEx:6497) expects to report topline and interim data in the second half of 2018 from up to four clinical trials with its lead drug candidate, varlitinib, for the treatment of biliary tract (BTC) and gastric cancers, and with ASLAN003 for the treatment of acute myeloid leukemia (AML).
Read MoreFor the first time in a century, administration of epidural needles is being transformed with a smart device developed by closely-held Omeq Medical, which has completed a proof of concept (POC) preclinical study, is currently preparing for FDA submission, and expects to initiate first-in-human trials later this year.
Read MoreCenturion BioPharma, a newly-created private subsidiary of CytRx (NASDAQ:CYTR) is currently in discussions with a number of pharma companies for a strategic alliance to continue development of its patient-identifying companion diagnostic and Linker-Activated Drug Release (LADR) anti-cancer drug candidates.
Read MoreClosely-held Intellijoint Surgical plans to improve patients’ lives by providing every orthopaedic surgeon with their surgical 3D solution that provides real-time intraoperative measurements to ensure accurate size selection and positioning of artificial implants during total hip arthroplasty (THA), which involves replacement of the damaged portion of the hip with artificial components.
Read MoreClosely-held Kardium hopes to receive marketing approval in Europe in the fourth quarter of 2018 and launch its breakthrough Globe mapping and ablation system of cardiac tissue for the treatment of atrial fibrillation (AF), the most common heart rhythm disorder where the atrium quivers instead of beating in regular rhythm.
Read MoreImagin Medical’s (CSE:IME; OTC:IMEXF) i/Blue Imaging System is expected to improve physicians’ ability to detect bladder cancer with minimally invasive endoscopes and reduce recurrence by dramatically improving the urologist’s ability to visualize, identify and remove cancerous cells.
Read MoreClosely-held XOR Labs hopes to dramatically increase the number of lungs suitable for transplantation with its Ex-Vivo Lung Perfusion (EVLP) technology.
Read MoreNanoSphere Health Sciences (CSE:NSHS; OTC:NSHSF) has developed a newly-patented delivery technology that increases the bioavailability and bioactivity of its Evolve line of gel-like cannabinoids for the treatment of pain, inflammation and anxiety.
Read MoreSince developing and validating SETALUM, a versatile vascular sealant in 2013, closely-held, Paris-based Gecko Biomedical is now poised to seek FDA approval for SETALUM, validate new programs, and open a state-of-the-art manufacturing facility in Northern France.
Read MoreFrance’s Nanobiotix (Euronext:NANO) is hoping to change the paradigm for cancer treatment with a single nanomedicine applicable across oncology for millions of patients.
Read MoreIn addition to several large ongoing investigator-sponsored studies in Europe and Canada using its autoRIC device for automated remote ischemic conditioning (RIC), closely-held CellAegis Devices expects its own U.S. pivotal trial for the treatment of elective percutaneous coronary intervention (ePCI) to complete enrolment before the end of 2018.
Read MoreOn the heels of positive data from its PALISADE pivotal trial, Aimmune Therapeutics (NASDAQ:AIMT) plans to submit a biologics license application with the FDA by the end of 2018 for its peanut allergy therapy, AR101.
Read MoreDuring the past four years, closely-held Cyclica has developed and validated a patented structure-based and AI-augmented proteome-screening platform, known as Ligand Express.
Read MoreSweden’s Moberg Pharma (OMX:MOB) is focused on maximizing the potential of its market leading position in over-the-counter sales of topical dermatology products to drive development of new therapies for the treatment of nail fungus and mouth pain, especially in cancer patients.
Read MoreClosely-held Tear Film Innovations plans to formally launch at two upcoming medical conferences its iLux medical device to treat Meibomian gland dysfunction, the leading cause of dry eye disease.
Read More
